menu search

VINC / Vincerx Pharma receives FDA clearance for early-stage leukemia trial

Vincerx Pharma receives FDA clearance for early-stage leukemia trial
Vincerx Pharma shares moved higher after the biopharmaceutical company announced it has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration to commence a clinical trial of its investigational therapeutic VIP943 for patients with acute myeloid leukemia and myelodysplastic syndrome. Read More
Posted: Aug 22 2023, 10:09
Author Name: Proactive Investors
Views: 060887

VINC News  

Vincerx Pharma To Present Three Posters at ASH 2023 in December

By GlobeNewsWire
November 2, 2023

Vincerx Pharma To Present Three Posters at ASH 2023 in December

VIP943 poster supports selectivity and safety of lead CD123 ADC, VIP943, currently in Phase 1 VIP924 poster shows this novel CXCR5-ADC compares favora more_horizontal

Vincerx Pharma receives FDA clearance for early-stage leukemia trial

By Proactive Investors
August 22, 2023

Vincerx Pharma receives FDA clearance for early-stage leukemia trial

Vincerx Pharma shares moved higher after the biopharmaceutical company announced it has received Investigational New Drug (IND) clearance from the U.S more_horizontal


Search within

Pages Search Results: